ATE527349T1 - Nervenregeneration - Google Patents

Nervenregeneration

Info

Publication number
ATE527349T1
ATE527349T1 AT05762470T AT05762470T ATE527349T1 AT E527349 T1 ATE527349 T1 AT E527349T1 AT 05762470 T AT05762470 T AT 05762470T AT 05762470 T AT05762470 T AT 05762470T AT E527349 T1 ATE527349 T1 AT E527349T1
Authority
AT
Austria
Prior art keywords
nerve
population
dna sequence
area near
cultured cells
Prior art date
Application number
AT05762470T
Other languages
English (en)
Inventor
Chang Kim
Kwan Hee Lee
Original Assignee
Tissuegene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tissuegene Inc filed Critical Tissuegene Inc
Application granted granted Critical
Publication of ATE527349T1 publication Critical patent/ATE527349T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05762470T 2004-06-23 2005-06-23 Nervenregeneration ATE527349T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58262704P 2004-06-23 2004-06-23
PCT/US2005/021993 WO2006002202A2 (en) 2004-06-23 2005-06-23 Nerve regeneration

Publications (1)

Publication Number Publication Date
ATE527349T1 true ATE527349T1 (de) 2011-10-15

Family

ID=35782307

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05762470T ATE527349T1 (de) 2004-06-23 2005-06-23 Nervenregeneration

Country Status (11)

Country Link
US (2) US20060014288A1 (de)
EP (1) EP1784486B1 (de)
JP (1) JP4576426B2 (de)
KR (1) KR100917403B1 (de)
CN (1) CN101031645B (de)
AT (1) ATE527349T1 (de)
AU (2) AU2005258101B2 (de)
CA (2) CA2571318C (de)
DK (1) DK1784486T3 (de)
ES (1) ES2376332T3 (de)
WO (1) WO2006002202A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
WO2004094592A2 (en) 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
WO2007002512A2 (en) * 2005-06-23 2007-01-04 Tissuegene, Inc. Neuroprotective effective compound
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
EP2142205B1 (de) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin Peptide für erhöhte Vaskularisierung im Gewebe mit reduzierter Durchblutung
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
RU2469421C2 (ru) * 2007-10-12 2012-12-10 Панасоник Корпорэйшн Векторный квантователь, инверсный векторный квантователь и способы
WO2009110215A1 (ja) * 2008-03-03 2009-09-11 独立行政法人 科学技術振興機構 繊毛細胞の分化誘導方法
WO2013188744A1 (en) * 2012-06-15 2013-12-19 Baylor College Of Medicine Perineurium derived adult stem cells and methods of use
US10595754B2 (en) 2014-03-13 2020-03-24 Sano Intelligence, Inc. System for monitoring body chemistry

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
US6723698B2 (en) * 1991-03-11 2004-04-20 Curis, Inc. Methods and compositions for the treatment of motor neuron injury and neuropathy
PT653942E (pt) * 1992-07-31 2003-11-28 Curis Inc Regeneracao e reparacao de nervos induzidos por morfogenios
EP1716864A1 (de) * 1993-08-26 2006-11-02 Genetics Institute, LLC Neuronale Regeneration mit menschlichen morphogenischen Knochenproteinen
US7011827B2 (en) * 1993-11-09 2006-03-14 Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
CA2334075A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. Bone morphogenic protein
US6743613B2 (en) * 1999-04-23 2004-06-01 Human Genome Sciences, Inc. Lysyl-oxidase HOHEC84 polynucleotides
AU7355500A (en) * 1999-09-08 2001-04-10 Genetics Institute Inc. Bmp-9 compositions and methods for inducing differentiation of cholinergic neurons
US6696410B1 (en) * 1999-09-27 2004-02-24 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
CN1319423A (zh) * 2001-02-19 2001-10-31 南通医学院 神经再生素及其生产方法和用途
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
US20050013870A1 (en) * 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
US20080286323A1 (en) * 2004-01-19 2008-11-20 Nsgene A/S Human Therapeutic Cells Secreting Nerve Growth Factor

Also Published As

Publication number Publication date
CA2571318C (en) 2011-06-07
EP1784486A4 (de) 2007-10-17
CN101031645A (zh) 2007-09-05
JP4576426B2 (ja) 2010-11-10
US20220241433A1 (en) 2022-08-04
DK1784486T3 (da) 2012-01-16
EP1784486A2 (de) 2007-05-16
JP2008504269A (ja) 2008-02-14
AU2005258101A1 (en) 2006-01-05
ES2376332T3 (es) 2012-03-13
US20060014288A1 (en) 2006-01-19
KR20070039554A (ko) 2007-04-12
CN101031645B (zh) 2011-06-08
AU2009201827A1 (en) 2009-05-28
AU2009201827B2 (en) 2013-01-31
KR100917403B1 (ko) 2009-09-14
CA2735272A1 (en) 2006-01-05
WO2006002202A3 (en) 2006-10-12
EP1784486B1 (de) 2011-10-05
AU2005258101B2 (en) 2009-08-27
WO2006002202A2 (en) 2006-01-05
CA2571318A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
AU2009201827B2 (en) Nerve regeneration
Berdien et al. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer
MX2020008470A (es) Vectores de adn no virales y usos de estos para la produccion de anticuerpos y proteinas de fusion.
ATE412761T1 (de) Methode um rekombinante proteine in cho zellen zu exprimieren
EP2366787A3 (de) Codonoptimierte IL-15- und IL-15R-Alpha-Gene zur Expression von Säugetierzellen
David et al. Magnetic cell sorting purification of differentiated embryonic stem cells stably expressing truncated human CD4 as surface marker
ATE286118T1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
EP1697521A4 (de) Multiplasmid-system zur erzeugung des grippevirus
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
DK2048236T3 (da) Genekspressionsteknik
WO2020186207A8 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
WO2017214569A1 (en) Genome-edited nk cell and methods of making and using
ATE438727T1 (de) Optimierung von transgenexpression in säugetierzellen
WO2004076626A3 (en) Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
WO2007055823A3 (en) Gpcr expressing cell lines and antibodies
DE69635513D1 (de) Menschliche pancreas zellinien: entwicklungen und anwendungen
US20250340868A1 (en) Polynucleotides encoding linked antigens and uses thereof
AR024122A1 (es) Metodo para la estabilizacion intensificada de proteinas y produccion de lineas celulares que sirven para la produccion de dichas proteinas estabilizadas
SG163592A1 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
ATE338826T1 (de) Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
WO2007002512A3 (en) Neuroprotective effective compound
WO2006104609A3 (en) Isolated myeloid-like bone marrow cell populations and methods of treatment therewith

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties